Using Surfactant to Treat Adult ARDS
Author Information
Author(s): Warren J. Davidson, Del Dorscheid, Roger Spragg, Michael Schulzer, Najib T. Ayas
Primary Institution: University of British Columbia
Hypothesis
Can exogenous pulmonary surfactant improve outcomes in adult patients with acute respiratory distress syndrome (ARDS)?
Conclusion
Exogenous surfactant may improve oxygenation but has not been shown to improve mortality.
Supporting Evidence
- 251 articles were identified, but only 5 studies met the inclusion criteria for analysis.
- Treatment with pulmonary surfactant did not reduce mortality compared to the control group.
- Subgroup analysis showed no significant difference in mortality based on surfactant type.
Takeaway
Doctors tried using a special liquid called surfactant to help people with serious breathing problems, but it didn't really help them live longer, just made it a bit easier to breathe.
Methodology
A systematic review and meta-analysis of randomized controlled trials comparing surfactant treatment to standard therapy in ARDS patients.
Potential Biases
Potential bias due to differences in study quality and randomization methods.
Limitations
Variability in surfactant types, delivery methods, and patient populations across studies.
Participant Demographics
Adult patients with ARDS, including those with sepsis and other causes of lung injury.
Statistical Information
P-Value
0.11
Confidence Interval
95% CI 0.73, 1.30
Statistical Significance
p=0.11
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website